Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma

Brittany E. Givens; Sean M. Geary; Aliasger K. Salem

doi:10.2217/imt-2017-0142

Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma

Brittany E. Givens
, Sean M. Geary
, Aliasger K. Salem

Producción científica: Review article › revisión exhaustiva

27 Citas (Scopus)

Resumen

Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.

Idioma original	English
Páginas (desde-hasta)	595-604
Número de páginas	10
Publicación	Immunotherapy
Volumen	10
N.º	7
DOI	https://doi.org/10.2217/imt-2017-0142
Estado	Published - jun 2018

Nota bibliográfica

Publisher Copyright:
© 2018 Future Medicine Ltd.

Financiación

Brittany E Givens acknowledges fellowship support from the Alfred P. Sloan Foundation, the University of Iowa Graduate College and the National GEM Consortium. Aliasger K Salem acknowledges support from NIH P30 ES005605, U01ES027252 01, and the Lyle and Sharon Bighley Chair of Pharmaceutical Sciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Financiadores	Número del financiador
National GEM Consortium
Graduate College, University of Iowa
National Institutes of Health (NIH)	U01ES027252 01
National Institutes of Health/National Institute of Environmental Health Sciences	P30ES005605
Alfred P Sloan Foundation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Acceder al documento

10.2217/imt-2017-0142

Otros archivos y enlaces

Citar esto

@article{3553a5370bfa493eb5b4d78477437f0a,

title = "Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma",

abstract = "Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.",

keywords = "allergic asthma, CpG-ODN, nanoparticles, prophylactic treatment, Th1 cytokines, Th2 cytokines, therapeutic treatment",

author = "Givens, \{Brittany E.\} and Geary, \{Sean M.\} and Salem, \{Aliasger K.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Future Medicine Ltd.",

year = "2018",

month = jun,

doi = "10.2217/imt-2017-0142",

language = "English",

volume = "10",

pages = "595--604",

number = "7",

}

TY - JOUR

T1 - Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma

AU - Givens, Brittany E.

AU - Geary, Sean M.

AU - Salem, Aliasger K.

PY - 2018/6

Y1 - 2018/6

N2 - Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.

AB - Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.

KW - allergic asthma

KW - CpG-ODN

KW - nanoparticles

KW - prophylactic treatment

KW - Th1 cytokines

KW - Th2 cytokines

KW - therapeutic treatment

UR - https://www.scopus.com/pages/publications/85047870012

UR - https://www.scopus.com/pages/publications/85047870012#tab=citedBy

U2 - 10.2217/imt-2017-0142

DO - 10.2217/imt-2017-0142

M3 - Review article

C2 - 29569508

AN - SCOPUS:85047870012

SN - 1750-743X

VL - 10

SP - 595

EP - 604

JO - Immunotherapy

JF - Immunotherapy

IS - 7

ER -

Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto